Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Technology / CEPI Funds Ebola Bundibugyo Vaccine...
Tech vaccine development

CEPI Funds Ebola Bundibugyo Vaccine Development

Analysis based on 36 articles · First reported May 22, 2026 · Last updated Jun 03, 2026

Sentiment
60
Attention
6
Articles
36
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The significant funding commitments from Coalition for Epidemic Preparedness Innovations, GAVI, and World Bank Group to develop Ebola Bundibugyo vaccines are expected to positively impact the pharmaceutical and biotechnology sectors, particularly for companies like Moderna, Serum Institute of India, and Merck & Co. The accelerated vaccine development could lead to new revenue streams and enhance the public image of these entities, while also mitigating the economic disruption caused by the outbreak in Democratic Republic of the Congo and Uganda.

pharmaceuticals biotechnology public health
Event Summary

Global health organizations are accelerating efforts to develop vaccines against the Ebola Bundibugyo strain, which is causing an outbreak in Democratic Republic of the Congo and Uganda. The Coalition for Epidemic Preparedness Innovations (CEPI) has committed approximately $60 million, with up to $50 million going to Moderna for its mRNA-based vaccine candidate. CEPI also invested in vaccine candidates from the University of Oxford, manufactured by Serum Institute of India, and the International AIDS Vaccine Initiative. The World Health Organization has declared the outbreak a public health emergency. Other funders, including GAVI and the World Bank's Pandemic Fund, have also committed substantial financial support to the Ebola response. The goal is to expedite trials and ensure access to effective vaccines, despite challenges like the unpredictable nature of vaccine development and the security situation in Democratic Republic of the Congo.

Key Actions
95 Moderna expanded collaboration Coalition for Epidemic Preparedness Innovations
86 Coalition for Epidemic Preparedness Innovations committed funding Moderna
86 World Health Organization revised risk assessment Democratic Republic of the Congo
80 World Health Organization declared emergency
74 United States — Centers for Disease Control and Prevention requested guidance
70 Coalition for Epidemic Preparedness Innovations invested International AIDS Vaccine Initiative
70 Serum Institute of India lined up to produce
60 GAVI committed funding
60 World Bank Group announced grants
60 United Kingdom provided funding Democratic Republic of the Congo
47 World Bank Group mobilized financing
47 United Nations released funds
Entities Involved
ngo
Coalition for Epidemic Preparedness Innovations
The Coalition for Epidemic Preparedness Innovations (CEPI) is a key funder, committing approximately $60 million to accelerate the development of Ebola Bundibugyo vaccines, and is crucial in coordinating the global response.
Importance 100 Sentiment 50
stock
Moderna
Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.
Importance 95 Sentiment 70
cnt
Democratic Republic of the Congo
The Democratic Republic of the Congo is experiencing an outbreak of Ebola Bundibugyo, with 282 confirmed cases and 42 deaths, making it the primary location for vaccine development and trials.
Importance 80 Sentiment 20
per
Teresa Lambe
Professor Teresa Lambe, Calleva Head of Vaccine Immunology at the University of Oxford Vaccine Group, is a lead scientist in the development of the new Ebola vaccine. Her expertise is crucial to the project's success.
Importance 80 Sentiment 70
ngo
World Health Organization
The World Health Organization (WHO) has declared the outbreak a public health emergency and is involved in monitoring cases and coordinating the global health response.
Importance 70 Sentiment 40
priv
Serum Institute of India
The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.
Importance 60 Sentiment 50
ngo
International AIDS Vaccine Initiative
The International AIDS Vaccine Initiative (IAVI) received an initial $3.2 million from CEPI to develop a single-dose Bundibugyo vaccine candidate using technology similar to Merck's Ervebo.
Importance 60 Sentiment 50
cnt
United Kingdom
The United Kingdom is providing up to £20 million to contain the Ebola outbreak in the Democratic Republic of the Congo and Uganda, supporting international efforts and frontline health workers.
Importance 60 Sentiment 30
per
Tedros Adhanom Ghebreyesus
Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, has been instrumental in declaring the public health emergency and communicating the escalating risk of the Ebola outbreak.
Importance 60 Sentiment 50
ngo
GAVI
GAVI, a global vaccine alliance, committed up to $50 million to the Ebola response, contributing to the overall funding for combating the outbreak.
Importance 50 Sentiment 50
alliance
World Bank Group
The World Bank's Pandemic Fund announced up to $220.6 million in grants, providing significant financial support to the Ebola response.
Importance 50 Sentiment 50
cnt
Uganda
Uganda has confirmed nine cases of Ebola Bundibugyo, including one death, indicating the regional spread of the outbreak.
Importance 40 Sentiment 20
alliance
United Nations
The United Nations released $60 million from its Central Emergency Response Fund to accelerate the response to the Ebola outbreak in the region, providing crucial financial support.
Importance 40 Sentiment 30
per
Stéphane Bancel
Stéphane Bancel>>>, CEO of Moderna>>>, expressed pride in the expanded collaboration, highlighting Moderna's>>> commitment to rapid response to infectious disease threats.
Importance 40 Sentiment 60
per
Richard Hatchett
Dr. Richard Hatchett>>>, CEO of Coalition for Epidemic Preparedness Innovations>>>, emphasized the urgency of funding to advance safe and effective vaccines against the Bundibugyo virus.
Importance 40 Sentiment 60
+ 4 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.